S&P 500 Consumer Staples Sector SEC Filings — October 22, 2026

Net sales up 4.0% YoY to $23,276M with organic sales also +4.0% (2% volume, 1% mix), showing volume-led top-line growth

FY2027 all-in sales growth guidance raised to 2-4% and organic sales, EPS and cash return guidance maintained, signaling confidence in the core plan

Operating income up 1.4% to $5,937M, showing modest operating leverage despite cost pressure

Core gross margin fell 150 bps (140 bps commodity costs, 140 bps reinvestments, offset by 120 bps productivity), indicating pricing power is not fully covering input costs

Currency-neutral core EPS flat YoY; the reported +1% core EPS growth was entirely FX-driven, so underlying earnings growth is nil

Net earnings attributable to P&G fell 0.4% to $4,731M from $4,750M while diluted EPS rose 1.0%, reflecting share count reduction rather than profit growth

Cost of products sold grew 7.3%, outpacing 4.0% sales growth, confirming the margin squeeze in the period

Long-term debt declined to $21,897M from $22,842M with $747M retired during the quarter, a modest deleveraging signal on the long-dated stack

Health Care segment volume declined 2.9% and Oral Care unit volume fell, offsetting pricing gains in those segments

Cash and equivalents rose to $15,365M from $9,942M, providing liquidity buffer for the Thorne acquisition and near-term maturities

Core gross margin down 150 bps YoY with cost of goods growing 7.3% vs 4.0% sales growth; sustained if commodity inflation persists into FY2027

Debt due within one year jumped 51% to $17,028M from $11,296M QoQ; maturity wall must be refinanced at higher interest costs (interest expense +13.2%)

$182M pre-tax FX translation loss in other comprehensive income (vs $12M a year earlier) drove total OCI loss of $189M and is a recurring headwind flagged in guidance

Currency-neutral core EPS flat; reported growth depends on FX tailwinds and buybacks, so earnings momentum is fragile if currency reverses

~$0.79/share FY2027 headwind from commodities, higher interest expense, lower non-operating income and FX must be absorbed to hold EPS guidance

Health Care volume -2.9% and Oral Care unit declines indicate pricing-led growth may be eroding consumer demand in specific categories

Net earnings attributable to P&G -0.4% YoY despite 4.0% sales growth shows sales growth is not converting to bottom-line growth

Thorne acquisition added to sales guidance, but integration and deal-related interest costs add execution risk to a flat-earnings quarter

Guidance raised to 2-4% all-in sales growth reflects Thorne contribution; accretion to top line could re-rate growth expectations if margins stabilize

120 bps of gross productivity savings already delivered in Q1; if sustained, it offsets roughly 80% of the 150 bps margin hit and supports a margin recovery path

Sales growth of 4.0% with 1% mix suggests pricing and premiumization continue to offset elevated costs

$747M long-term debt retired in the quarter and total long-term debt down $945M QoQ; continued paydown would improve credit metrics

Dividend and buyback commitments held despite headwinds, supporting total shareholder return for income-oriented holders

If FX headwinds ease, the reported EPS base (currently flat on a neutral basis) could benefit from translation reversal, given the $182M OCI loss in the period

Cash up 55% QoQ to $15.4B provides a buffer for short-term maturities and optionality for opportunistic capital deployment

P&G's 140 bps commodity headwind and 150 bps core gross margin decline illustrate that staples pricing is struggling to fully pass through input cost inflation; monitor peer filings for similar patterns

4.0% sales growth with only 2% volume indicates reliance on pricing and mix; sustained low-volume growth raises questions about the durability of top-line expansion across the group

Interest expense up 13.2% and a shift to short-term debt highlight how higher rates are compressing below-the-line earnings, which is a broader sector headwind given the sector's leverage profile

A $182M translation loss and FX cited as a guidance headwind show how currency movements are masking underlying constant-currency performance for globally diversified staples companies

The Thorne acquisition, reflected in raised all-in guidance, signals continued use of acquisitions to supplement organic growth in personal care and wellness categories

Track how the $17.0B of debt due within one year is refinanced and at what coupons, given the 13.2% rise in interest expense (next 10-Q, expected early February 2027)

Monitor whether the 150 bps core gross margin decline narrows in Q2 FY2027 as productivity savings build (next earnings release, expected around late January 2027)

Watch for a reversal of the -2.9% Health Care volume and Oral Care unit declines; sustained weakness would challenge the volume-led growth thesis

Look for disclosure of Thorne's revenue and earnings contribution and any deal-related costs in subsequent filings

Watch for any move from maintained EPS guidance toward the low end, given the ~$0.79/share cumulative headwind

Track whether the $182M OCI translation loss persists, which would signal continued currency pressure on reported results

Confirm that dividend and buyback commitments are maintained as cash shifts toward short-term debt service